Stryker Launches New Tendon Fixation Device System
September 15, 2021 at 08:05 am EDT
Share
Stryker’s Trauma & Extremities division has launched its Citrelock™ Tendon Fixation Device System. The new system provides surgeons a differentiated design via a tendon thread featuring a resorbable technology, known as Citregen™, that has unique chemical and mechanical properties for orthopaedic surgical applications. Stryker will debut Citrelock at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting, Sept. 22-25, 2021, in Charlotte, N.C. The Citrelock Tendon Fixation Device System offers surgeons: A controlled and homogeneous resorption process that prevents bulk degradation and chronic inflammation. Compressive strength that is comparable to cortical bone with a modulus comparable to cancellous bone. Citregen contains citrate, calcium, and phosphate molecules that are inherent to the bone anatomy. Material polymer structure that mimics the extracellular matrix protein network. Citregen maintains structural integrity during the healing phase, while the implant is replaced by host tissue over time.
Stryker Corporation is one of the world's leaders in designing, manufacturing, and selling orthopedic equipments. Net sales break down by family of products as follows:
- surgical equipments and neurotechnology products (57.5%): electric motorized surgical instruments, surgical navigation systems, endoscopy equipment, digital imaging systems, neurosurgery equipments, neurovascular devices, etc. The group also offers hospital beds, gurneys, stretchers, and emergency room equipment;
- orthopedic implants (42.5%): joint prostheses, traumatology implants, micro-implants, orthopedic cement, orthobiology products, etc. The group also provides spinal implants.
At the end of 2022, the group had 48 production sites worldwide.
Net sales are distributed geographically as follows: the United States (73.9%), Europe/Middle East/Africa (12.7%), Asia/Pacific (10.2%) and other (3.2%).